Global Head of R&D, Daiichi Sankyo
Appears in 1 story
Leads R&D at Enhertu's originator company
The U.S. Food and Drug Administration (FDA) cleared AstraZeneca and Daiichi Sankyo's Enhertu for two new uses in early-stage HER2-positive breast cancer in May 2026. The drug, already a standard for advanced disease, now enters the window where the goal is cure, not control.
Updated May 18
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
